{"product_id":"anti-14-3-3-epsilon-ywhae-rabbit-monoclonal-antibody-bha21008640","title":"Anti-14-3-3 epsilon YWHAE Rabbit Monoclonal Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eThis product is an anti-YWHAE antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone HHD-25; isotype Rabbit IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-14-3-3 epsilon YWHAE Rabbit Monoclonal Antibody catalog # M01687. Tested in WB, IHC, ICC\/IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e YWHAE (14-3-3 protein epsilon).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody format:\u003c\/strong\u003e Monoclonal; clone HHD-25; isotype Rabbit IgG.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHost:\u003c\/strong\u003e Rabbit.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human,Mouse,Rat (confirm in your model system with appropriate controls).\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThis description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eYWHAE (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Reported cellular localization context: Cytoplasm . Melanosome . Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Tissue expression notes (as provided): Detected in endothelial cells in vascular tissue throughout the body. May appear at the surface of neural crest cells during their embryonic migration. Appears to be limited to vascular smooth muscle in normal adult tissues. Associated with tumor progression and the development of metastasis in human malignant melanoma. Expressed most strongly on metastatic lesions and advanced primary tumors and is only rarely detected in benign melanocytic nevi and thin primary melanomas with a low probability of metastasis.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eResearch context keywords from the source record include: Adapters,Cell Type Marker,Cytoplasmic,Neural Signal Transduction,Neurology Process,Neuron Marker,Neuroscience,Signal Transduction,Signaling Pathways,Stem Cells,Synapse Marker.\u003c\/li\u003e\n\u003cli\u003eCurrent studies often focus on connecting target abundance\/localization to pathway perturbations across models, tissues, and cell states.\u003c\/li\u003e\n\u003cli\u003eQuantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eWestern blotting (WB):\u003c\/strong\u003e assess relative target abundance across samples, treatments, or time-points.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunohistochemistry (IHC):\u003c\/strong\u003e evaluate spatial distribution of target-positive staining in tissue architecture.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunofluorescence\/ICC (IF\/ICC):\u003c\/strong\u003e visualize subcellular localization patterns and cell-to-cell heterogeneity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFlow cytometry:\u003c\/strong\u003e quantify target-positive populations and compare shifts in marker distributions.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWorkflow ideas (metafield): Validate YWHAE antibody specificity using KO\/KD control samples (WB\/IF\/IHC as appropriate), Detect YWHAE expression by Western blot in cell or tissue lysates, Detect YWHAE in FFPE tissue sections by immunohistochemistry, Localize YWHAE by immunofluorescence\/immunocytochemistry in cultured cells, Quantify YWHAE-positive cells by flow cytometry in single-cell suspensions\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e \u003cli\u003eConsider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.\u003c\/li\u003e\n\u003cli\u003eApparent molecular weight may vary by sample type and processing (observed MW: 120 kDa; calculated MW: 29174 MW).\u003c\/li\u003e\n\u003cli\u003eControl concepts: include appropriate negative controls (e.g., isotype, KO\/KD samples) and orthogonal validation when feasible.\u003c\/li\u003e \u003c\/ul\u003e \u003ch2\u003eAdditional product details (from the source record)\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight (observed):\u003c\/strong\u003e 120 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCellular localization (provided):\u003c\/strong\u003e Cytoplasm . Melanosome . Identified by mass spectrometry in melanosome fractions from stage I to stage IV.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTissue details (provided):\u003c\/strong\u003e Detected in endothelial cells in vascular tissue throughout the body. May appear at the surface of neural crest cells during their embryonic migration. Appears to be limited to vascular smooth muscle in normal adult tissues. Associated with tumor progression and the development of metastasis in human malignant melanoma. Expressed most strongly on metastatic lesions and advanced primary tumors and is only rarely detected in benign melanocytic nevi and thin primary melanomas with a low probability of metastasis.\u003c\/li\u003e\n\u003c\/ul\u003e \u003c!-- Sources (internal): - Antibodies — a laboratory manual overview — Cold Spring Harbor Protocols — https:\/\/cshprotocols.cshlp.org\/ - UniProt Knowledgebase — UniProt — https:\/\/www.uniprot.org\/ - NCBI Gene — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Antibody validation and reproducibility — Nature methods (collections) — https:\/\/www.nature.com\/collections\/ - Immunohistochemistry\/Immunofluorescence basics — NIH \/ NCBI Bookshelf — https:\/\/www.ncbi.nlm.nih.gov\/books\/ --\u003e","brand":"Boster Bio","offers":[{"title":"100 uL\/vial \/ Unconjugated","offer_id":53071945007469,"sku":"M01687","price":370.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/m01687-wb.jpg?v=1772618566","url":"https:\/\/www.ebiohippo.com\/products\/anti-14-3-3-epsilon-ywhae-rabbit-monoclonal-antibody-bha21008640","provider":"BioHippo","version":"1.0","type":"link"}